Edition:
United Kingdom

Cadila Healthcare Ltd (CADI.NS)

CADI.NS on National Stock Exchange of India

346.60INR
23 May 2018
Change (% chg)

Rs3.55 (+1.03%)
Prev Close
Rs343.05
Open
Rs344.40
Day's High
Rs353.95
Day's Low
Rs342.60
Volume
676,727
Avg. Vol
960,334
52-wk High
Rs560.00
52-wk Low
Rs341.20

Latest Key Developments (Source: Significant Developments)

Cadila Healthcare To Sell 12.5 Mln Shares Of JV To Bayer (South East Asia)
Friday, 27 Apr 2018 

April 27 (Reuters) - Cadila Healthcare Ltd ::SAYS CO IS SELLING 12.5 MILLION SHARES OF JV TO BAYER (SOUTH EAST ASIA) PTE BY EXECUTING SHARE PURCHASE DEAL.  Full Article

Cadila Healthcare Says Zydus Gets Final Approval From U.S. FDA For Diclofenac Sodium Topical Solution
Thursday, 19 Apr 2018 

April 19 (Reuters) - Cadila Healthcare Ltd ::SAYS ZYDUS GETS FINAL APPROVAL FROM U.S. FDA FOR DICLOFENAC SODIUM TOPICAL SOLUTION.SAYS IT SOLUTION TO BE MANUFACTURED AT GROUP'S TOPICAL MANUFACTURING FACILITY AT AHMEDABAD.  Full Article

Cadila Healthcare Says ‍Zydus Gets U.S. FDA Nod For Metoprolol Succinate Extended-Release Tablets USP​
Monday, 26 Mar 2018 

March 26 (Reuters) - Cadila Healthcare Ltd ::SAYS ‍ZYDUS RECEIVES FINAL APPROVAL FROM USFDA FOR METOPROLOL SUCCINATE EXTENDED-RELEASE TABLETS USP​.  Full Article

Cadila Healthcare Says U.S.FDA Completed Inspection At Co's Dabhasa API Facility​
Friday, 19 Jan 2018 

Jan 19 (Reuters) - Cadila Healthcare Ltd ::SAYS USFDA ‍ SUCCESSFULLY COMPLETED INSPECTION AT CO'S DABHASA API FACILITY​.SAYS USFDA DID NOT ISSUE ANY OBSERVATION AFTER INSPECTION.  Full Article

Glenmark Pharmaceuticals Launches Biosimilar Of Adalimumab In India
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Glenmark Pharmaceuticals Ltd ::LAUNCHES BIOSIMILAR OF ADALIMUMAB IN INDIA.  Full Article

Cadila Healthcare's Zydus Gets Final Nod From U.S. FDA For Clomipramine Hydrochloride Capsules
Friday, 29 Dec 2017 

Dec 29 (Reuters) - Cadila Healthcare Ltd ::SAYS ZYDUS GETS FINAL APPROVAL FROM U.S. FDA FOR CLOMIPRAMINE HYDROCHLORIDE CAPSULES USP.SAYS CAPSULES TO BE MANUFACTURED AT GROUP'S FORMULATIONS MANUFACTURING FACILITY IN AHMEDABAD.  Full Article

Cadila Healthcare Says ‍Zydus Gets U.S.FDA Nod For Drug to Treat Hypertension, Chest Pain
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Cadila Healthcare Ltd ::SAYS ‍ZYDUS RECEIVES FINAL APPROVAL FROM USFDA FOR NIFEDIPINE EXTENDED-RELEASE TABLETS USP​.DRUG USED TO TREAT HYPERTENSION, CHEST PAIN WILL BE MANUFACTURED AT CO'S FORMULATIONS MANUFACTURING FACILITY AT SEZ, AHMEDABAD.  Full Article

Cadila Healthcare Says ‍Zydus Got USFDA Nod For Two Drugs
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Cadila Healthcare Ltd ::‍ZYDUS GETS FINAL APPROVAL FROM USFDA FOR PRAMIPEXOLE DIHYDROCHLORIDE EXTENDED-RELEASE TABLETS & NITROFURANTOIN CAPSULES USP (MACROCRYSTALS)​.PRAMIPEXOLE DIHYDROCHLORIDE TO TREAT SYMPTOMS OF PARKINSON'S DISEASE; NITROFURANTOIN TO TREAT ACUTE URINARY TRACT INFECTION.SAYS BOTH DRUGS TO BE MANUFACTURED AT CO'S FORMULATIONS MANUFACTURING FACILITY AT MORAIYA, AHMEDABAD‍​.  Full Article

Cadila Healthcare's Zydus Gets Final Nod From U.S. FDA For Clozapine Tablets
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Cadila Healthcare Ltd ::SAYS ZYDUS GET FINAL NOD FROM U.S. FDA FOR CLOZAPINE TABLETS USP.DRUG USED TO TREAT SCHIZOPHRENIA ; DRUG TO BE MANUFACTURED AT GROUP'S FORMULATIONS MANUFACTURING FACILITY AT AHMEDABAD.  Full Article

Cadila Healthcare Says Zydus Gets Tentative Approval From U.S. FDA For Pregabalin Capsules
Friday, 1 Dec 2017 

Dec 1 (Reuters) - Cadila Healthcare Ltd ::SAYS ZYDUS GETS TENTATIVE APPROVAL FROM U.S. FDA FOR PREGABALIN CAPSULES.SAYS CAPSULE TO BE MANUFACTURED AT GROUP'S FORMULATIONS FACILITY AT MORAIYA, AHMEDABAD.  Full Article

BRIEF-Cadila Healthcare Gets Exit Price For Sale Of Shares To Bayer (South East Asia)

* CADILA HEALTHCARE - GOT EXIT PRICE FOR SALE OF SHARES TO BAYER (SOUTH EAST ASIA) PTE LTD IN TERMS OF JV AGREEMENT Source text: http://bit.ly/2HNe3Uu Further company coverage: